600351.SS
Strong BuyFull HouseAI neutralYabao Pharmaceutical Group Co., Ltd · Healthcare · China · $687M
CNY 6.82 +1.8% · close 30 Sep · scored 3 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Yabao Pharmaceutical is currently engaging in shareholder-friendly capital allocation, specifically an active, note-worthy share buyback program. While this indicates management's belief in the intrinsic value of the business, the stock lacks the massive thematic velocity seen in our energy or gold plays. It is worth holding as a defensive play during a period of market instability.
ABOUT YABAO PHARMACEUTICAL GROUP CO., LTD
Read
Yabao Pharmaceutical Group Co., Ltd. develops, manufactures, and markets pharmaceuticals, specializing in pediatric Traditional Chinese Medicine and cardiovascular drugs. The company's competitive moat is anchored by its market-leading pediatric patches, which enjoy high brand loyalty in China's OTC market. It is a niche pharmaceutical player with strong brand equity and a robust pediatric product pipeline.
FINANCIAL SUMMARY (CNY)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.7B | 2.9B | 2.7B | 2.2B | -6.2% | 2.2B |
| EPS (CNY) | 0.14 | 0.26 | 0.34 | 0.46 | 48.7% | 0.47 |
| Shares | 770.0M | 770.0M | 720.0M | 692.0M | -10.1% | 692.0M |
| Debt | 441.7M | 209.0M | 95.7M | 36.2M | -56.6% | 38.2M |
| Equity | 3.0B | 3.0B | 2.9B | 2.9B | -1.0% | — |
| Op CF | 460.5M | 497.6M | 471.7M | 573.8M | 7.6% | 598.6M |
| Inv CF | -96.7M | -127.4M | -33.7M | 96.5M | — | — |
| Fin CF | -178.6M | -446.8M | -425.3M | -428.1M | — | — |
Calmer than 77% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600351.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 600351.SS | Yabao Pharmaceutical Group Co., Ltd(you) | $687M | 99 | Strong Buy |
| 2877.HK | China Shineway Pharmaceutical Group Limited | $791M | 99 | Strong Buy |
| 000915.SZ | Shandong Wit Dyne Health Co.,Ltd. | $837M | 98 | Strong Buy |
| 600479.SS | ZhuZhou QianJin Pharmaceutical Co.,Ltd | $909M | 93 | Strong Buy |
| 000650.SZ | Renhe Pharmacy Co.,Ltd | $1.1B | 96 | Strong Buy |
| 9989.HK | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $732M | 85 | Strong Buy |
| 600976.SS | Jianmin Pharmaceutical Group Co.,Ltd. | $612M | 85 | Strong Buy |
| 002275.SZ | Guilin Sanjin Pharmaceutical Co., Ltd. | $1.1B | 91 | Strong Buy |
| 1681.HK | Consun Pharmaceutical Group Limited | $1.5B | 99 | Strong Buy |
| 0719.HK | Shandong Xinhua Pharmaceutical Company Limited | $513M | 88 | Strong Buy |
Peer medians: ROE 4.3% · P/E 27.8x · Gross margin 53.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.